Coronavirus update: India's COVID-19 caseload rises to 1,04,66,595 with 16,311 fresh infections

The death toll reached 1,51,160 with 161 more fatalities, the lowest in the last seven-and-half-months, the data updated at 8 am showed.

PTI
January 11, 2021 / 10:23 AM IST

With 16,311 new coronavirus cases being reported in a span of 24 hours, the lowest in around six-and-half months, India's COVID-19 tally rose to 1,04,66,595, while the recoveries have surged to 1,00,92,909, according to the Union Health Ministry's data updated on Monday.

The death toll reached 1,51,160 with 161 more fatalities, the lowest in the last seven-and-half-months, the data updated at 8 am showed.

The number of people who have recuperated from the disease surged to 1,00,92,909, pushing the national COVID-19 recovery rate to 96.43 percent, while the casefatality rate was recorded at 1.44 percent.

The COVID-19 active caseload remained below three lakh. There are 2,22,526 active coronavirus infections in the country which comprise2.13 percent of the total caseload, the data stated.

India's COVID-19 tally had crossed the 20 lakh-mark on August 7, 30 lakh on August 23, 40 lakh on September 5 and50 lakh on September 16.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19.

According to the ICMR, 18,17,55,831 samples have been tested so far with 6,59,209 samples being tested on Sunday.
PTI
TAGS: #coronavirus #Current Affairs #India
first published: Jan 11, 2021 10:18 am